Ranbaxy Laboratories Ltd (RANB.BO)

RANB.BO on Bombay Stock Exchange

564.95INR
3:50pm IST
Price Change (% chg)

Rs-14.20 (-2.45%)
Prev Close
Rs579.15
Open
Rs579.15
Day's High
Rs582.05
Day's Low
Rs560.30
Volume
183,606
Avg. Vol
150,061
52-wk High
Rs596.85
52-wk Low
Rs253.95

RANB.BO

Chart for RANB.BO

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 0.72
Market Cap (Mil.): Rs245,440.09
Shares Outstanding (Mil.): 424.01
Dividend: --
Yield (%): --

Financials

  RANB.BO Industry Sector
P/E (TTM): -- 35.82 36.29
EPS (TTM): -28.64 -- --
ROI: -- 18.85 18.13
ROE: -- 19.57 18.95
Search Stocks

Ranbaxy posts loss on provision for U.S. settlement

MUMBAI - Generic drugmaker Ranbaxy Laboratories Ltd posted a net loss for the quarter to end-June after making a provision related to "ongoing settlement discussions" with U.S. government authorities.

29 Jul 2014

UPDATE 1-India's Ranbaxy posts loss on provision for US settlement

* Loss of 1.86 bln rupees due to one-off 2.4 bln provision

29 Jul 2014

India's Ranbaxy Laboratories posts loss in June quarter

MUMBAI, July 29 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by local rival Sun Pharmaceutical Industries Ltd, posted a net loss in the June quarter hit by a one-time provision.

29 Jul 2014

Drugmaker Novartis to eke out more cost savings to lift margins

ZURICH - Swiss drugmaker Novartis posted a quarterly rise in sales that missed expectations and said it would focus on eking out gradual cost savings to boost margins as it prepares a radical business overhaul.

17 Jul 2014

India caps price of 108 more medicines; drugmakers to take hit

MUMBAI - India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms such as Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

14 Jul 2014

UPDATE 1-India caps price of 108 more medicines; drugmakers to take hit

* Move aimed towards making drugs more affordable in India

14 Jul 2014

India caps prices of 108 more medicines; drugmakers to take hit

MUMBAI, July 14 - India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

14 Jul 2014

BSE Sensex edges higher; defensive stocks surge

MUMBAI - The BSE Sensex and Nifty rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained after rival Accenture Plc reported robust quarterly revenue growth.

27 Jun 2014

Ranbaxy gets FDA approval for Novartis's Diovan generic

WASHINGTON/MUMBAI - Ranbaxy Laboratories Ltd  has received approval from the U.S. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's  blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.

27 Jun 2014

Indian shares edge higher; defensives surge

* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained

27 Jun 2014

Earnings vs. Estimates

Search Stocks